The Sleepy Patient on an MAOI
Mr. L, 44, has treatment-resistant depression and has taken tranylcypromine 30 mg BID for eight months with partial response. He presents to your outpatient clinic reporting two weeks of worsening low mood, hypersomnia, and a 5-lb weight gain. He was recently started on quetiapine 50 mg at bedtime by his PCP for insomnia and has been taking diphenhydramine 50 mg nightly as well. Today his BP is 152/94 (baseline 118/76), HR 104, and he is visibly drowsy but oriented. He denies headache, chest pain, neck stiffness, or visual changes. He reports eating aged cheddar and salami at a family gathering two days ago. He has no suicidal ideation.
1. What is your immediate assessment and disposition?
Read the worked answer
This is a suspected hypertensive reaction to tyramine superimposed on serotonergic/anticholinergic burden, but the absence of headache, neck stiffness, chest pain, or neuro symptoms makes a full hypertensive crisis less likely at 152/94. Still, the combination is unsafe and requires action today.
- Do not simply observe. Repeat BP after 10 minutes of rest; assess for end-organ symptoms (chest pain, neuro deficits, visual change).
- Culprits: (1) dietary tyramine (aged cheese, cured meats) with a nonselective MAOI; (2) diphenhydramine adds anticholinergic sedation and can worsen hypertension; (3) quetiapine is not contraindicated but adds orthostasis/sedation and may be contributing to hypersomnia and weight gain.
- Disposition: If BP remains elevated with any symptom, send to ED. If asymptomatic and BP trending down, manage outpatient same day: stop diphenhydramine, review tyramine-restricted diet in writing, and coordinate with PCP to stop quetiapine (or at minimum reduce and reassess).
- Document the interaction counseling and follow up within 48–72 hours.
2. How do you counsel this patient about his MAOI diet and his other medications?
Read the worked answer
Counsel explicitly and in writing, using the mechanism so he can generalize:
- Tyramine is a indirect sympathomimetic that MAO-A normally degrades; with MAO inhibited, tyramine triggers norepinephrine release → hypertensive surge.
- High-risk foods: aged/cured cheeses, cured and fermented meats (salami, pepperoni, fermented sausage), tap beer and some craft beers, draft beer, fermented soy (soy sauce, miso, tempeh), sauerkraut, fava beans, marmite/yeast extracts, improperly stored or spoiled foods.
- Lower-risk: fresh cheeses (cottage, cream, ricotta), fresh meat, most packaged foods - but portion and freshness matter.
- Medications to avoid: sympathomimetics (pseudoephedrine, phenylephrine), meperidine, tramadol, other serotonergic agents, linezolid, St. John's wort, and OTC cold/allergy products. Diphenhydramine is not a classic pressor but is a poor choice here given sedation and anticholinergic load; recommend a non-drug sleep plan and, if needed, a safer agent after review.
- Teach warning signs: sudden severe headache, neck stiffness, chest pain, palpitations, visual changes → ED immediately.
3. Two weeks later his BP is 124/78 and mood is unchanged. What is your next pharmacologic step and what must you verify first?
Read the worked answer
Partial response after 8 months at 30 mg BID is a fair trial; before augmenting, verify:
- Adherence and dose - confirm he is actually taking 30 mg BID (MAOIs are often underdosed).
- Dietary and drug interactions - rule out ongoing tyramine or sympathomimetic exposure.
- Medical workup - TSH, CBC, CMP, B12; rule out hypothyroidism, anemia, sleep apnea (his hypersomnia and weight gain raise this).
- Psychosocial - psychotherapy engagement, substance use.
If workup is negative and he is adherent, options include:
- Increase tranylcypromine toward 40–60 mg/day in divided doses with BP monitoring (max ~60 mg/day), or
- Augment with lithium or a second-generation antipsychotic (aripiprazole, quetiapine) - but note quetiapine caused sedation/weight gain here, so aripiprazole or lithium may be preferable; avoid serotonergic agents (SSRIs, SNRIs, clomipramine, tramadol, meperidine).
Document informed consent about hypertensive risk and follow BP closely after any change.